Concord Biotech (NSE:CONCORDBIO, BOM:543960) has acquired a 75% in US-based Stellon Biotech for $15,000, making it a subsidiary, to expand its business operations in the US, according to a Wednesday filing to the Indian stock exchanges.
The company subscribed 15 million equity shares of Stellon Biotech at $0.0001 per share.
Stellon is currently in its pre-revenue phase and was formed to support the marketing and commercialization of products developed by Concord Biotech.
The equity shares against the current investment will be allotted within 90 days.
The company's shares were down over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.